Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000584983 | SCV000693324 | likely pathogenic | not provided | 2017-10-01 | criteria provided, single submitter | clinical testing | |
Molecular Genetics Laboratory, |
RCV001199544 | SCV001162665 | pathogenic | Retinitis pigmentosa | 2020-01-09 | criteria provided, single submitter | research | |
Prevention |
RCV000584983 | SCV002759671 | likely pathogenic | not provided | 2019-03-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002530868 | SCV003467357 | pathogenic | Primary ciliary dyskinesia | 2021-12-19 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with RPGR (ORF15)-related conditions. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the RPGR (ORF15) protein in which other variant(s) (p.Leu1130Lysfs*13) have been determined to be pathogenic (PMID: 22264887; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 493514). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the gnomAD database. This sequence change creates a premature translational stop signal (p.Glu869*) in the RPGR (ORF15) gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 284 amino acid(s) of the RPGR (ORF15) protein. |